Asker Asmi, MD
Critical Care Medicine · Riverview, MINPI 1649240177
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 570 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among critical care medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 570 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Mylan Specialty L.p.$1K
- GSK$1K
- Boehringer Ingelheim$1K
- Grifols USA, LLC$654
- Regeneron Healthcare Solutions, Inc.$392
- plus $4K from 40 others
What the payments were for
- Food & beverage$10,83198%
- Education$2042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,035 in reported general payments places this provider in the 95th percentile of 177 critical care medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 30 | $382,420 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 389 | $353,298 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 14 | $254,350 |
| Advair HfaFluticasone Propion/Salmeterol | 373 | $182,512 |
| Spiriva RespimatTiotropium Bromide | 253 | $158,477 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 98 | $65,507 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 314 | $53,260 |
| DuleraMometasone/Formoterol | 135 | $51,636 |
| Incruse ElliptaUmeclidinium Bromide | 113 | $45,830 |
| SymbicortBudesonide/Formoterol Fumarate | 134 | $38,713 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 138 | $32,700 |
| Tiotropium Bromide | 44 | $26,260 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $21,078 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $17,740 |
| Spiriva HandihalerTiotropium Bromide | 23 | $16,158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,304 | $561,975309 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $1,339 | $416,868539 claims |
| Grifols USA, LLCProlastin C | $654 | $254,35014 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,588 | $104,220232 claims |
| MerckDulera | $37 | $51,636135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 critical care medicine providers in Michigan.
Other critical care medicine in Riverview
- Syed RazaRiverview$913
- Angel Peralta-AvilaDetroit$147K
- Moumen AsbahiTroy$81K
- Mujahed AbbasLansing$28K
- Abdulrazak AlchakakiSouthfield$19K
- Narayana GandhamSaint Joseph$18K
- Sara MirzaAnn Arbor$12K
- Andrew EasowDearborn$10K
- Jeffery WiltGrand Rapids$10K
- Furqan SiddiqiSaint Joseph$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.